← 產業報告目錄
Chemotherapy-Induced Anemia Market Size, Share & Trends Analysis Report, By Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, and Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-27頁數 180報告編號 INSIGHTACE-51a4eb9b9a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Chemotherapy-Induced Anemia Market stood at USD 2.4 Bn in 2023, and is projected to reach USD 3.9 Bn by 2031, recording a CAGR of 6.5% from 2024 through 2031.
At its core, Chemotherapy-Induced Anemia pertains to landscape are growingly turning to these solutions to meet contemporary demands.
The market's upward path is supported by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Chemotherapy Induced Anemia Market Snapshot
Chapter 4. Global Chemotherapy Induced Anemia Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Range of Anemia Estimates & Trend Analysis
5.1. by Range of Anemia & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Range of Anemia:
5.2.1. Mild Anemia
5.2.2. Moderate Anemia
5.2.3. Severe Anemia
5.2.4. Life-Threatening Anemia
Chapter 6. Market Segmentation 2: by Treatment Type Estimates & Trend Analysis
6.1. by Treatment Type & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment Type:
6.2.1. RBC Transfusion
6.2.2. Erythropoiesis-stimulating agents (ESAs)
6.2.3. Iron Supplementation
Chapter 7. Market Segmentation 3: by Drug Type Estimates & Trend Analysis
7.1. by Drug Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Type:
7.2.1. Epogen Injection
7.2.2. Procrit Injection
7.2.3. Androxy Oral
7.2.4. Aranesp Injection
7.2.5. Epoetin Alfa Injection
7.2.6. Others
Chapter 8. Market Segmentation 4: by End-User Estimates & Trend Analysis
8.1. by End-User & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Ambulatory Surgical Centers
8.2.4. others
Chapter 9. Chemotherapy Induced Anemia Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.1.2. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.1.3. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.1.4. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.1.5. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.2.2. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.2.3. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.2.4. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.2.5. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.3.2. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.3.3. Asia-Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.3.4. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.3.5. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.4.2. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.4.3. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.4.4. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.4.5. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.5.2. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.5.3. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.5.4. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.5.5. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Astellas Pharma Inc.
10.2.2. Blausen Medical
10.2.3. Dr. Reddy's Laboratories Ltd.
10.2.4. Elsevier Inc.
10.2.5. F. Hoffmann-La Roche Ltd
10.2.6. FibroGen, Inc.
10.2.7. GlaxoSmithKline PLC
10.2.8. Healio
10.2.9. Johnson & Johnson
10.2.10. Karger AG
10.2.11. Novartis AG
10.2.12. Pfizer Inc.
10.2.13. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們